

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50062/006001		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No. 10/018,235		
				Applicant Raouf Rekik		
				Filing Date May 22, 2002		
				Group 1614		
				IDS Filed October 22, 2004		
(37 C.F.R. § 1.98(b))						
U.S. PATENTS						
Examiner=s Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS						
Examiner=s Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
KW	Holman et al., "Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39," <i>BMJ</i> 317:713-720 (1998).					
EXAMINER	40 Widdows			DATE CONSIDERED 3-9-05		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						